Rare diseases
Investigational molecules
Locations
Back to Denmark631 clinical trials in Aarhus, Denmark across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in DenmarkKliniske-Forsoeg.dk(opens in a new tab)Study on the Safety and Effects of ORG-129 in Patients with Fibrostenotic Crohn's Disease
DenmarkStudy on the Effectiveness and Safety of Ropeginterferon and Bosutinib for Patients with Chronic Myeloid Leukemia
DenmarkStudy of trastuzumab with chemotherapy and immunotherapy combination for first-line treatment in patients with HER2-positive esophageal squamous cell cancer
DenmarkStudy of Nimorazole Treatment Based on Hypoxia Profile in Head and Neck Cancer Patients Receiving Radiotherapy with Cisplatin
DenmarkStudy on the Safety and Effectiveness of AZD8630 for Adults with Uncontrolled Asthma at Risk of Exacerbations
DenmarkStudy of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups
DenmarkStudy of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease
DenmarkStudy of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment
DenmarkStudy on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis
DenmarkStudy of secukinumab and prednisone combination therapy for patients with giant cell arteritis (GCA): Evaluation of treatment effectiveness and safety
DenmarkStudy on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation
DenmarkStudy on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment
DenmarkThe busiest research cities in the country
What the registry says about research in the country
Clinical research in cardiovascular diseases encompasses several important areas of investigation. Studies are examining novel approaches to preventing and treating complications following acute myocardial infarction, including the management of left ventricular thrombosis through comparative trials of different anticoagulation strategies. Additional research focuses on reducing cardiovascular risk in patients with metabolic conditions, exploring intensive care strategies and pharmacological interventions targeting cardiovascular death and heart failure hospitalization.
These investigations aim to establish more effective treatment protocols and improve outcomes for patients at elevated cardiovascular risk, with particular attention to both efficacy and safety considerations in diverse patient populations.
Research into nervous system diseases includes studies addressing both acute and chronic neurological conditions. A significant focus is placed on patients with covert brain infarction, examining whether antiplatelet therapy and lipid-lowering treatments can reduce future vascular events. Investigations also explore disease-modifying therapies for early-stage Parkinson's disease, comparing novel biological agents against placebo to evaluate their potential in slowing disease progression.
These trials seek to establish evidence-based approaches for both preventing silent cerebrovascular disease progression and modifying the course of neurodegenerative conditions through innovative therapeutic interventions.
Type 1 diabetes research represents a major therapeutic focus, with multiple trials investigating strategies to prevent complications and preserve organ function. Studies are examining the effects of various pharmacological agents on chronic kidney disease progression in diabetic patients, particularly focusing on reducing albuminuria. Research also addresses cardiovascular complications in this population, testing comprehensive care approaches that combine multiple interventions.
These investigations aim to establish more effective methods for preventing end-organ damage and improving long-term outcomes in patients with metabolic diseases, addressing both renal and cardiovascular complications.
Clinical trials in male urogenital diseases focus on metastatic or high-risk recurrent prostate cancer managed with androgen deprivation therapy. Research is investigating whether commonly used cardiovascular medications might delay disease progression, specifically examining the development of castration resistance. These studies explore the potential repurposing of established therapies to improve outcomes in advanced prostate cancer.
This research aims to identify new approaches that could extend the effectiveness of standard hormone therapy and potentially improve survival outcomes for patients with advanced prostate cancer.
Comprehensive research into high-risk neuroblastoma involves multi-phase randomized trials comparing different treatment strategies. Studies are evaluating various induction chemotherapy regimens, comparing single versus tandem high-dose chemotherapy approaches, and assessing different radiotherapy protocols for residual disease. Additional investigations focus on chemoimmunotherapy combinations for patients with insufficient initial response to standard treatment.
These trials aim to optimize treatment protocols for this aggressive childhood cancer, seeking to improve survival rates while managing treatment-related toxicity through careful comparison of therapeutic approaches.
Research in acute myeloid leukemia focuses on pediatric patients with refractory or relapsed disease harboring specific genetic alterations including KMT2A-rearrangements, NUP98-rearrangements, or NPM1 mutations. Studies are evaluating novel targeted therapies in combination with established chemotherapy regimens, assessing response rates according to pediatric-specific criteria.
These investigations seek to improve outcomes for children with high-risk leukemia who have limited treatment options, focusing on molecularly targeted approaches tailored to specific genetic abnormalities.
Clinical trials in respiratory tract diseases focus on pulmonary sarcoidosis with or without extrapulmonary manifestations. Research employs seamless phase 1b/2 designs, beginning with dose-escalation studies to establish safety and tolerability of novel biological agents, followed by proof-of-concept investigations. The primary efficacy goal involves reducing dependence on oral corticosteroid therapy, addressing a significant unmet need in chronic sarcoidosis management.
These studies aim to develop alternative treatment options that could reduce the burden of long-term corticosteroid use and its associated complications in patients with chronic sarcoidosis.
Research in immune system diseases includes investigations of atopic dermatitis, with particular emphasis on long-term safety and efficacy evaluation of novel biological therapies. Studies provide extended follow-up for participants who completed earlier clinical trials, characterizing the safety profile of continued treatment in patients with moderate to severe disease.
These extension studies are crucial for understanding the long-term benefit-risk profile of emerging therapies for chronic inflammatory skin conditions, providing essential data for clinical decision-making.
Trials in non-small cell lung cancer focus on patients with KRAS G12C mutations who have previously untreated advanced or metastatic non-squamous disease. Research compares novel targeted therapy combinations against standard chemotherapy regimens, evaluating both progression-free survival and overall survival as primary endpoints.
These investigations represent important advances in precision oncology, seeking to establish whether molecularly targeted approaches can improve outcomes compared to conventional chemotherapy in genetically selected patients with advanced lung cancer.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
